Although the interest in the potential disease-modifying effects of MAO-B inhibitors has increased, and the effects of rasagiline in patients with early PD have been investigated [22], their use in this indication has not been approved by the Food and Drug Administration (FDA). This evidence concerns the gene MAOB and Parkinson disease.